Configurations:
AST: item 10104018*
ID/AST: item 10102018
Each configuration contains:
48-channel disposable test cassette
Reagent cartridge
Sample vial
Easier for the lab.
Earlier for clinicians.
Fast MIC results. Direct from positive blood cultures. Now with optional ID, and affordably priced.
—imagine the potential for patients.
Hear firsthand the difference
fast MICs are making
Independent studies show the BC kit provides identification and susceptibility results with MICs about 40 hours faster than current methods.*
*based on peer-reviewed publications comparing IVD-cleared methods through June 2019. Actual time to results may vary.
Pair rapid MICs with
your existing workflow
Now you can use your existing ID test to get fast AST results using the Accelerate PhenoTest BC kit.
It’s your lab after all, so do it your way.
AST: request item 10104018*
ID / AST: request item 10102018
*AST configuration is in development and available Summer 2021. ID/AST configuration is FDA-cleared for use direct from positive blood cultures.
Clinical need
- Timely escalation to effective therapy reduces mortality
- Timely escalation to effective therapy reduces hospital length of stay
- De-escalation can improve patient outcomes
Timely escalation to effective therapy reduces mortality
Impact of Time to Definitive Therapy on Mortality4
Empiric therapy may not be adequate in up to 25% of patients with bloodstream infections (BSIs).4 Shortening the time horizon from empiric to optimal therapy requires susceptibility results with the MIC for 52% of patients with BSIs.5
4 Retamar et al. Antimicrob Agents Chemother. 2012 Jan;56(1):472-8
5 Huang et al. Clin Infect Dis. 2013 Nov;57(9):1237-45
Timely escalation to effective therapy reduces hospital length of stay
Impact of Effectiveness of Antibiotic on Hospital Length of Stay (Gram-negative sepsis)6
Reducing hospital length of stay (LOS) by two days reduces broad spectrum antibiotic exposure that may increase the risk of HAIs, C. difficile infection, and increase risk of community-acquired resistance. It also substantially reduces cost of care.
6 Shorr et al, Crit Care Med 2011. Jan; 39(1): 46-51
De-escalation can improve patient outcomes
% CDI Incidence by Number of Simultaneous Drug Classes Administered
Reducing the time frame from empiric broad-spectrum antibiotic coverage to optimal therapy has been shown to dramatically reduce the incidence of C. difficile in patients with BSIs.7
Reporting antimicrobial susceptibility results approximately 40 hours faster than conventional methods gives clinicians the data required to optimize therapy 1-2 days faster.
7 Tartof et al, 2015. Infect. Control Hosp. Epidemiol. 2015;36(12) :1409–1416
Gram-Positive
View:
Identification |
Ampicilin |
Ceftaroline |
Daptomycin |
Linezolid |
Vancomycin |
Methicillin resistance (Cefoxitin) |
||
|---|---|---|---|---|---|---|---|---|
| S. aureus | ||||||||
| S. lugdunensis | ||||||||
| CNS spp. | ||||||||
| E. faecalis | ||||||||
| E. faecium | ||||||||
| Streptococcus spp. |
| S. aureus | S. lugdunensis | CNS spp. | E. faecalis | E. faecium | Streptococcus spp. | |
|---|---|---|---|---|---|---|
| Identification | ||||||
| Ampicilin | ||||||
| Ceftaroline | ||||||
| Daptomycin | ||||||
| Linezolid | ||||||
| Vancomycin | ||||||
| Methicillin resistance (Cefoxitin) |
Gram-Negative
View:
Identification |
Ampicillin- Sulbactam |
Piperacillin- Tazobactam |
Cefepime |
Ceftazidime |
Ceftriaxone |
Ertapenem |
Meropenem |
Amikacin |
Gentamicin |
Tobramycin |
Ciprofloxacin |
Aztreonam |
||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E. coli | ||||||||||||||
| Klebsiella spp. | ||||||||||||||
| Enterobacter spp. | ||||||||||||||
| Proteus spp. | ||||||||||||||
| Citrobacter spp. | ||||||||||||||
| S. marcescens | ||||||||||||||
| P. aeruginosa | ||||||||||||||
| A. baumannii |
| E. coli | Klebsiella spp. | Enterobacter spp. | Proteus spp. | Citrobacter spp. | S. marcescens | P. aeruginosa | A. baumannii | |
|---|---|---|---|---|---|---|---|---|
| Identification | ||||||||
| Ampicillin- Sulbactam |
||||||||
| Piperacillin- Tazobactam |
||||||||
| Cefepime | ||||||||
| Ceftazidime | ||||||||
| Ceftriaxone | ||||||||
| Ertapenem | ||||||||
| Meropenem | ||||||||
| Amikacin | ||||||||
| Gentamicin | ||||||||
| Tobramycin | ||||||||
| Ciprofloxacin | ||||||||
| Aztreonam |
Yeast
Identification |
|
|---|---|
| Candida albicans | |
| Candida glabrata |
Klebsiella spp.
K. oxytoca
K. pneumoniae
Enterobacter spp.
E. cloacae
E. aerogenes
Proteus spp.
P. mirabilis
P. vulgaris
Citrobacter spp.
C. freundii
C. koseri
CNS spp.
S. capitis
S. epidermidis
S. haemolyticus
S. hominis
S. lugdunensis
S. warneri
Streptococcus spp.
S. agalactiae
S. gallolyticus
S. mitis
S. oralis
S. pneumoniae
Specifications
The Accelerate PhenoTest™ BC kit is run directly with positive blood culture samples.
Store BC kits at 2-8°C. Do not store at room temperature.
Automatic or manual ID entry options are available for AST configuration of Accelerate PhenoTest BC kit.
1 Kit
Dimensions:
2.5 h x 8 w 12 l in
6.2 h x 20 w x 30 l cm
Weight:
2.1 lb
950 g
Storage: 2.8°C
5 Pack, including packaging
Dimensions:
13 h x 12.5 w x 13 l in
33 h x 32.5 w x 33 l cm
Weight:
33 lb
15 kg
Publications
Jul 13, 2021
Impact of the Accelerate PhenoTest® BC Kit on time to results for pathogens from bloodstream infections: IOAS (Improving Outcomes and Antibiotic Stewardship) study experience of 4 hospitals
ECCMID 2021
Jul 13, 2021
Evaluating the impact of the Accelerate PhenoTest® BC Kit on patients with bloodstream infections receiving ineffective empirical antibiotic treatment: IOAS study experience of 4 hospitals
ECCMID 2021
Jul 13, 2021
Antimicrobial use in patients with bloodstream infections from 4 hospitals in the Improving Outcomes and Antibiotic Stewardship (IOAS) study: a quasi-experimental multi-centre study of the Accelerate PhenoTest® BC Kit
ECCMID 2021